Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2019-12-05 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Penthrox Marketing Authorisation Application in Russia 2 pages 190.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 6 December 2019 regarding the acceptance of a Marketing Authorisation Application (MAA) for the drug Penthrox in Russia by the Russian Ministry of Health. It discusses regulatory progress, milestone payments, and company statements about the significance of this event. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a regulatory and commercial milestone rather than a financial report or detailed investor presentation. It is also relatively short (4269 characters) and serves as a news update on regulatory progress. Therefore, it fits best into the category of a Regulatory Filing (RNS), which is the fallback for general regulatory announcements and compliance updates that do not fit other specific categories.
2019-12-05 English
Penthrox IND approved in China 2 pages 152.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 November 2019 about the approval of an Investigative New Drug (IND) application by the Chinese National Medical Product Administration (NMPA) for the company's product Penthrox. It discusses regulatory progress and clinical study plans but does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (4845 characters) and serves as a news update on regulatory approval rather than a financial report or detailed investor presentation. It is not an annual or interim report, earnings release, or any form of detailed financial disclosure. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2019-11-20 English
Chairman's Address to Shareholders 2 pages 133.6KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 30 October 2019 containing addresses by the Chairman and CEO to shareholders. The content focuses on business updates, progress on regulatory approvals, product launches, clinical study results, and future outlook. There is no detailed financial data, no formal financial statements, and no indication that this is a full annual or interim report. The document resembles a presentation or speech given to shareholders, typically part of an Annual General Meeting or similar event. It is not a report publication announcement since it contains substantive content rather than just a notice. Therefore, the document best fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting.
2019-10-29 English
CEO Roadshow Presentation 24 pages 1.3MB
Annual Report Classification · 95% confidence The document is titled 'Medical Developments International October 2019' and contains detailed information about the company's products, market performance, clinical trials, regulatory progress, technology development, financial performance, and outlook. It includes financial figures such as cash receipts, net profit after tax, EBITDA, and dividends, indicating a comprehensive overview of the company's yearly activities and financial results. The presence of a fiscal year reference (FY19) and detailed financial and operational data suggests this is a full annual report rather than a brief announcement or presentation. The length of the document (15,000 characters) and the depth of content further support classification as an Annual Report (10-K). There is no indication that this is merely an announcement of a report or a certification, so it is not RPA or RNS. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2019-10-29 English
Results of Meeting 2 pages 144.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication to the Australian Securities Exchange regarding the results of the 2019 Annual General Meeting (AGM) of Medical Developments International Limited. It references Listing Rule 3.13.2 and section 251AA of the Corporations Act, which pertain to disclosure of voting results. The content includes detailed voting results for resolutions passed at the AGM, such as the remuneration report and director re-elections. The document is not the AGM presentation materials themselves but the official announcement of the voting outcomes. The document length is short (2259 characters), consistent with a voting results announcement rather than a full report or presentation. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-10-29 English
MVP signs new Manufacturing Development Project with CSIRO 2 pages 144.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 29 October 2019 from Medical Developments International Limited (MVP) about signing a new Manufacturing Development Project with CSIRO. It details the terms of the agreement, investment amounts, share issuance conditions, and quotes from executives. There is no financial report, earnings data, or regulatory filing referenced. The content is a corporate announcement about a new project and partnership, which fits the category of Capital/Financing Update (CAP) as it involves investment commitments and share issuance terms related to funding the project. The document length is about 5,099 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement. Therefore, the best classification is Capital/Financing Update (CAP).
2019-10-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.